This technology is a serologic test that measures the levels of circulating micro-RNAs (miRNAs) associated with low bone turnover renal osteodystrophy that may be used to monitor disease status guide therapeutic management.
Renal osteodystrophy is a highly prevalent bone metabolic disease caused by abnormal rates of bone turnover. Effective treatment requires an accurate assessment of bone turnover and tailored delivery of drugs that reduce or enhance turnover. Currently, the standard of care for estimating bone turnover are bone biopsies that are impractical for many patients, expensive, invasive, and may take months to obtain results.
This assay measures the levels of a subset of miRNAs present in serum that correlate with the rate of bone turnover. Diagnostic accuracy is further bolstered by also monitoring the serum levels of parathyroid hormone (PTH) and Bone-Specific Alkaline Phosphatase (BSAP). Through a simple blood draw, the non-invasive test provides an estimation of aberrant turnover that is significantly more accurate than existing blood biomarkers that presently are insufficient to inform treatment plans. Due to the ease of sampling and rapid output of results, this miRNA panel may be used to effectively monitor disease progression and guide therapeutic management of renal osteodystrophy with vitamin D analogs, calcimimetics and anti-osteoporotic agents.
This technology has been validated in patient cohorts with renal osteodystrophy.
IR CU18256
Licensing Contact: Ron Katz
